Bristol-Myers Squibb reports slight increase in second-quarter sales

Share this article:

Despite increased competition from generics, Bristol-Myers Squibb (BMS) reported a slight increase in its second-quarter sales results.

Second-quarter net sales were at $4.9 billion, up 1% over the same period a year earlier.

Sales of BMS' blood thinner Plavix, the company's top-selling drug, rebounded after a generic version made by Canadian generics company Apotex briefly entered the US market late last year.

Plavix sales were up 3.8% to $1.1 billion in the second-quarter from $1.0 billion.
 
A federal court judge recently upheld Plavix's patent exclusivity until 2011.

Plavix was the No. 2 selling drug behind Pfizer's Lipitor in 2005, with global sales of $5.9 billion.  
Second-quarter sales of schizophrenia drug Abilify were up 27% to $412 million.
 
Sales of AIDS drug Reyataz were rose 7.6% to $254 million.
 
Hypertension drugs Avapro and Avalide posted a combined 6.1% increase to $297 million.
 
Meanwhile, sales of oncology drug Erbitux dropped 5.8% to $162 from $172 million a year earlier. BMS pays royalties to ImClone Systems on Erbitux. Both companies recently announced that a late-stage study of the drug in lung-cancer patients didn't meet the primary endpoint of progression-free survival.

The company's once popular cholesterol drug Pravachol, which lost patent protection in April 2006, saw its sales shrink by 59% in the second-quarter to $132 million from $323 million in the year earlier period.  

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...